Search research articles
Contact Us
Filters
Showing results (141-150 of 165) with videos related to
Page
of 17
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
August 14, 2024
Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe
Isik S Johansen, Ashley Roen, Christian Kraef, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 9, 2018
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study
Robert M Grant, Sharon Mannheimer, James P Hughes, et al.
Plos Medicine
|
September 1, 2012
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings
Thomas B Campbell, Laura M Smeaton, N Kumarasamy, et al.
Annals of Internal Medicine
|
October 7, 2014
Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1
J L Lennox, R J Landovitz, H J Ribaudo, et al.
AIDS and Behavior
|
June 10, 2022
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)
Kenneth H Mayer, Krista Yuhas, K Rivet Amico, et al.
Annals of Internal Medicine
|
October 7, 2014
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial
Jeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, et al.
The Lancet. HIV
|
February 23, 2020
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study
Catherine A Koss, Edwin D Charlebois, James Ayieko, et al.
The Lancet. HIV
|
October 2, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
Mark A Marzinke, Brett Hanscom, Zhe Wang, et al.
The New England Journal of Medicine
|
October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
Diane V Havlir, Michelle A Kendall, Prudence Ive, et al.
The Lancet. HIV
|
May 11, 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
Lameck Chinula, Lauren Ziemba, Sean Brummel, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 165) with videos related to
Sort By:
Page
of 17
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
August 14, 2024
Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe
Isik S Johansen, Ashley Roen, Christian Kraef, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 9, 2018
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study
Robert M Grant, Sharon Mannheimer, James P Hughes, et al.
Plos Medicine
|
September 1, 2012
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings
Thomas B Campbell, Laura M Smeaton, N Kumarasamy, et al.
Annals of Internal Medicine
|
October 7, 2014
Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1
J L Lennox, R J Landovitz, H J Ribaudo, et al.
AIDS and Behavior
|
June 10, 2022
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)
Kenneth H Mayer, Krista Yuhas, K Rivet Amico, et al.
Annals of Internal Medicine
|
October 7, 2014
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial
Jeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, et al.
The Lancet. HIV
|
February 23, 2020
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study
Catherine A Koss, Edwin D Charlebois, James Ayieko, et al.
The Lancet. HIV
|
October 2, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
Mark A Marzinke, Brett Hanscom, Zhe Wang, et al.
The New England Journal of Medicine
|
October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
Diane V Havlir, Michelle A Kendall, Prudence Ive, et al.
The Lancet. HIV
|
May 11, 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
Lameck Chinula, Lauren Ziemba, Sean Brummel, et al.
Page
of 17